BUSINESS SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2018

Schedule of Segment Reporting Information, by Segment

The following table is a summary of segment information for the years ended December 31, 2018, 2017 and 2016. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses, and the gain on disposition of businesses associated with the dispositions of Focus Diagnostics (see Note 7). The accounting policies of the segments are the same as those of the Company as set forth in Note 2.



	2018			2017			2016
Net revenues:
DIS business	$	7,204		$	7,068		$	6,837
All other operating segments	327			334			377
Total net revenues	$	7,531		$	7,402		$	7,214

Operating earnings (loss):
DIS business	$	1,235		$	1,313		$	1,244
All other operating segments	47			52			64
General corporate activities	(181		)	(200		)	(31		)
Total operating income	1,101			1,165			1,277
Non-operating expenses, net	(175		)	(135		)	(191		)
Income before income taxes and equity in earnings of equity method investees	926			1,030			1,086
Income tax expense	(182		)	(241		)	(429		)
Equity in earnings of equity method investees, net of taxes	44			35			39
Net income	788			824			696
Less: Net income attributable to noncontrolling interests	52			52			51
Net income attributable to Quest Diagnostics	$	736		$	772		$	645

Depreciation and amortization expense for the years ended December 31, 2018, 2017 and 2016 were as follows:



	2018		2017		2016

DIS business	$	213	$	189	$	170
All other operating segments	6		6		6
General corporate	90		75		73
Total depreciation and amortization	$	309	$	270	$	249

Capital expenditures for the years ended December 31, 2018, 2017 and 2016 were as follows:



	2018		2017		2016

DIS business	$	330	$	219	$	264
All other operating segments	16		15		21
General corporate	37		18		8
Total capital expenditures	$	383	$	252	$	293

Net revenues by major service for the years ended December 31, 2018, 2017 and 2016 were as follows:



	2018		2017		2016

Routine clinical testing services	$	4,217	$	4,006	$	3,878
Gene-based and esoteric (including advanced diagnostics) testing services	2,409		2,449		2,335
Anatomic pathology testing services	578		612		624
All other	327		335		377
Total net revenues	$	7,531	$	7,402	$	7,214